Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Stroke. 2015 Aug 4;46(9):2628–2636. doi: 10.1161/STROKEAHA.115.010091

Figure 3. Rosiglitazone Improves Long-term Recovery of Neurological Function after MCAO.

Figure 3

A-B, Sensorimotor dysfunction was significantly attenuated in rosiglitazone (RSG)-treated mice up to 21 days after ischemia, as assessed by the Rotarod test (A) and corner test (B). Corner test performance was expressed by the percentage of right turns out of ten turn trials. The performance in the Rotarod test was expressed as the time spent on the rotating rod before falling off. C-D, The Morris water maze test was performed to measure cognitive deficits after cerebral ischemia. C, Latency to find the hidden platform in the cued test (spatial learning). D, Time spent in target quadrant in the probe test (memory consolidation). Data are expressed as mean ± SEM. A-C, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 vs vehicle. D, * P ≤ 0.05 vs sham, # P ≤ 0.05 vs vehicle. N=6-8 per group.